Why the study?
The role of ERK1/2 in cardiac fatty acid metabolism and diabetic cardiomyopathy remained unclear.
Does ERK1/2 inhibition by U0126 alleviate cardiac remodeling in diabetic mouse models?
Population
H9C2 cells and db/db and streptozotocin-induced diabetic mice
Comparison
Pharmacological ERK1/2 inhibition with U0126 vs untreated diabetic conditions
Design
In vitro and in vivo preclinical study
Authors
Loading...
Supports ERK1/2 as a research target in diabetic cardiomyopathy; leaves open translation to human therapy.
Does ERK1/2 inhibition by U0126 alleviate cardiac remodeling in diabetic mouse models?
Pharmacological inhibition of ERK1/2 alleviates cardiac remodeling in diabetic mice by reducing fatty acid metabolism, highlighting a potential therapeutic target for diabetic cardiomyopathy.
McLean et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: